Werewolf Therapeutics Inc (NASDAQ: HOWL)’s stock price has gone rise by 25.03 in comparison to its previous close of 0.80, however, the company has experienced a 5.43% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that – WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
Is It Worth Investing in Werewolf Therapeutics Inc (NASDAQ: HOWL) Right Now?
The stock has a 36-month beta value of 0.48. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HOWL is 33.12M, and at present, short sellers hold a 6.49% of that float. On May 13, 2025, the average trading volume of HOWL was 267.34K shares.
HOWL’s Market Performance
HOWL’s stock has seen a 5.43% increase for the week, with a 52.91% rise in the past month and a -24.81% fall in the past quarter. The volatility ratio for the week is 11.24%, and the volatility levels for the past 30 days are at 11.12% for Werewolf Therapeutics Inc The simple moving average for the past 20 days is 13.80% for HOWL’s stock, with a -40.37% simple moving average for the past 200 days.
Analysts’ Opinion of HOWL
Many brokerage firms have already submitted their reports for HOWL stocks, with JMP Securities repeating the rating for HOWL by listing it as a “Mkt Outperform.” The predicted price for HOWL in the upcoming period, according to JMP Securities is $12 based on the research report published on April 03, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see HOWL reach a price target of $9. The rating they have provided for HOWL stocks is “Outperform” according to the report published on August 24th, 2023.
Jefferies gave a rating of “Buy” to HOWL, setting the target price at $12 in the report published on June 06th of the previous year.
HOWL Trading at 3.48% from the 50-Day Moving Average
After a stumble in the market that brought HOWL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.55% of loss for the given period.
Volatility was left at 11.12%, however, over the last 30 days, the volatility rate increased by 11.24%, as shares surge +40.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.35% lower at present.
During the last 5 trading sessions, HOWL rose by +5.43%, which changed the moving average for the period of 200-days by -63.64% in comparison to the 20-day moving average, which settled at $0.8787. In addition, Werewolf Therapeutics Inc saw -32.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOWL starting from MPM BioVentures 2014, L.P., who sale 1,963 shares at the price of $1.05 back on Mar 27 ’25. After this action, MPM BioVentures 2014, L.P. now owns 3,208,793 shares of Werewolf Therapeutics Inc, valued at $2,061 using the latest closing price.
EVNIN LUKE, the Director of Werewolf Therapeutics Inc, sale 2,425 shares at $1.05 during a trade that took place back on Mar 27 ’25, which means that EVNIN LUKE is holding 4,309,860 shares at $2,546 based on the most recent closing price.
Stock Fundamentals for HOWL
Current profitability levels for the company are sitting at:
- -39.04 for the present operating margin
- 0.51 for the gross margin
The net margin for Werewolf Therapeutics Inc stands at -37.41. The total capital return value is set at -0.66. Equity return is now at value -82.81, with -50.84 for asset returns.
Based on Werewolf Therapeutics Inc (HOWL), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.52. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -15.81.
Currently, EBITDA for the company is -64.05 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of -15.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.09.
Conclusion
To sum up, Werewolf Therapeutics Inc (HOWL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
